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Idiopathic pulmonary ﬁbrosis is a progressive disease of unknown etiology characterized
by a dysregulated wound healing response that leads to fatal accumulation of ﬁbroblasts
and extracellular matrix (ECM) in the lung, which compromises tissue architecture and lung
function capacity. Injury to type II alveolar epithelial cells is thought to be the key event for
the initiation of the disease, and so far both genetic factors, such asmutations in telomerase
andMUC5B genes aswell as environmental components, like cigarette smoking, exposure
to asbestos and viral infections have been implicated as potential initiating triggers. The
injured epithelium then enters a state of senescence-associated secretory phenotype
whereby it produces both pro-inﬂammatory and pro-ﬁbrotic factors that contribute to the
wound healing process in the lung. Immune cells, like macrophages and neutrophils as
well as activated myoﬁbroblasts then perpetuate this cascade of epithelial cell apoptosis
and proliferation by release of pro-ﬁbrotic transforming growth factor beta and continuous
deposition of ECM stiffens the basement membrane, altogether having a deleterious
impact on epithelial cell function. In this review, we describe the role of the epithelium as
both a physical and immunological barrier between environment and self in the homeostatic
versus diseased lung and explore the potential mechanisms of epithelial cell injury and
the impact of loss of epithelial cell permeability and function on cytokine production,
inﬂammation, and myoﬁbroblast activation in the ﬁbrotic lung.
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INTRODUCTION
Idiopathic pulmonary ﬁbrosis (IPF) is a devastating, ﬁbroprolif-
erative chronic lung disorder with complex and as yet unknown
disease biology. The histopathology of IPF demonstrates a char-
acteristic heterogeneity: areas of normal parenchyma interspersed
with areas of paraseptal and subpleural ﬁbrosis (The Idiopathic
Pulmonary Fibrosis Clinical Research Network, 2012). At the
cellular level, IPF is characterized by alveolar epithelial injury, initi-
ation of inﬂammatory cascades, exaggerated pro-ﬁbrotic cytokine
expression, increased extracellular matrix (ECM) deposition, and
the development of ﬁbrotic lesions known as ﬁbroblast “foci”
(Wilson andWynn, 2009). IPFhas a heterogeneous clinical course,
with a median survival after diagnosis of only 2.5–3.5 years (King
et al., 2011). Althoughmuch of the pathogenesis is still to be eluci-
dated, ﬁbroblasts and epithelial cells, in particular type II alveolar
epithelial cells and myoﬁbroblasts are thought to be key drivers in
the initiation and progression of the disease, respectively (Sakai
and Tager, 2013). This review will focus on the epithelial cell,
explore the mechanisms of cell injury and their role in repair in
the ﬁbrotic lung, as well as interactions with other key effector cells
in IPF such as the ﬁbroblasts.
THE LUNG EPITHELIUM AS A PHYSICAL BARRIER AGAINST
FOREIGN INSULTS
The airway epithelium is a pseudo-stratiﬁed mucosal barrier
that consists of multiple cell types. It constitutes the ﬁrst bar-
rier of defense against environmental insults and infection by
providing not only a mechanical and physical barrier to impede
entry of foreign particles but also by its ability to orchestrate
both the innate and adaptive immune responses. The lower air-
way surface, where gas exchange takes place is mainly covered
by two types of alveolar epithelial cells, alveolar type I epithe-
lial cells (ATI) that cover 90% of the airway surface due to
their large ﬂattened phenotype and whose main function is gas
interchange, and alveolar type II epithelial cells (ATII) that are
the most abundant epithelial cell type and whose function is to
maintain the alveolar space by secretion of several types of sur-
factant proteins and other ECM components (Serrano-Mollar,
2012). The production of surfactant by ATII cells enables the gas
exchange tooccurby lowering the surface tensionwithin the alveoli
(Rackley and Stripp, 2012).
As well as alveolar epithelial cells in the alveolar compartment,
other epithelial cell types populate the lung; with secretory Clara
and goblet cells, ciliated, basal and neuroendocrine cells form-
ing the tracheo-bronchial pseudostratiﬁed epithelium (Figure 1).
Ciliated and secretory cells work in concert to clear the air-
way passages from micro-organisms, air pollutants and other
inhaled pathogens. Mucous and goblet cells produce and release
mucous into the apical surface of the epithelium thus trapping
foreign particles (Roche et al., 1993) which are then cleared out
by the action of ciliated cells beating in a rhythmic movement
in the ascending direction (Fahy and Dickey, 2010; Gras et al.,
2013). Mucous is a viscoelastic gel composed mainly of highly
charged glycoproteins called mucins, and also some anti-viral and
www.frontiersin.org January 2014 | Volume 4 | Article 173 | 1
“fphar-04-00173” — 2014/1/8 — 17:59 — page 2 — #2
Camelo et al. The epithelium in idiopathic pulmonary ﬁbrosis
FIGURE 1 |The adult lung epithelium is composed of various different
cell types. The tracheo-bronchial epithelium forms a pseudostratiﬁed layer
consisting of ciliated cells and secretory epithelial cells (Clara) and goblet cells.
Underneath this layer, human basal cells (thought to be epithelial progenitor
cells) are present at high numbers. Their numbers, however, decrease
dramatically as the lung progresses into the alveolar space. Neuroendocrine
cells can also be present that become innervated by ganglion cells. Their role
is thought to be of regulating cell proliferation and differentiation. The
respiratory bronchioles are still very poorly characterized and lead to the
alveoli, that are mostly lined by alveolar type I (ATI) and type II (ATII) cells.
anti-inﬂammatory components such as lysozyme, defensins, IgA,
and various cytokines (Nicholas et al., 2006). So far, 11 mucins
have been identiﬁed in humans, with MUC5AC and MUC5B
being predominant in human sputum (Rose et al., 2001). Mucin
production importantly becomes up-regulated following viral
infection to allow for better trapping and disposal of viral par-
ticles, however, over-production of mucous or over-proliferation
of mucous-producing cells (goblet cell hyperplasia) can have dele-
terious effects by creatingmucous plugs and thus leading to airway
obstruction (Vareille et al., 2011). The latter is a common feature
of several chronic lung diseases such as asthma, chronic obstruc-
tive pulmonary disease (COPD) and cystic ﬁbrosis (Rogers, 2004;
Hauber et al., 2006).
The epithelial integrity and permeability are maintained by
tight connections within the epithelial cell layer, such as tight
junctions, adherens junctions, and desmosomes. These cell–
cell junctions provide strong adhesion, maintaining mechanical
strength in the tissue, enabling communication between neigh-
boring cells and blocking the entry of viruses, bacteria or inhaled
allergens into the basolateral membrane where they can access
epithelial cell receptors and/or activate antigen-presenting cells
(Roche et al., 1993).
Mostly, the mature lung is non-proliferative, with prolonged
survival of resident cells. However, in the event of damage to the
epithelial layer following inﬂammation, infection, or exposure to
airway pollutants, it is critical that the site of injury is quickly
closed and replaced by newly differentiated epithelial cells in order
tomaintain an effective physical barrier. Several studies have iden-
tiﬁed some epithelial cell types and also progenitor cells in the
lung as potential key regenerative players in the replacement of
the epithelium after damage, although most of these remain rela-
tively controversial. In the alveoli, ATII cells have been shown to
proliferate and differentiate into type I cells (Cardoso and Whit-
sett, 2008; Ghosh et al., 2013) and in the conducting airways, basal
cells (Figure 1), in contact with the basement membrane but not
the airway lumen were found capable of long-term self-renewal
and differentiation into ciliated and non-ciliated cell types in
vivo (Hong et al., 2004). Lastly, neuroendocrine cells form clus-
ters called neuroepithelial bodies, and there is some evidence
these may play a role in regulating epithelial cell proliferation
and differentiation of neighboring cells (Hoyt et al., 1991). The
signaling and transcriptional programs that are activated in this
process of wound healing can resemble and somewhat recapitulate
early lung developmental programs (Rackley and Stripp, 2012).
Thesepathways typically becomedysregulatedduring chronic lung
disease.
THE EPITHELIUM IN INTERSTITIAL LUNG DISEASE
Alteration of the phenotype of alveolar epithelial cells is a cen-
tral feature in IPF, whereby continuous damage to the epithelium
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and concomitant cell apoptosis are thought to contribute to the
perpetuation of the ﬁbrotic scarring (Jin and Dong, 2011). The
causative event that initiates the ﬁbrotic cascade in IPF is still
unknown, although apoptosis or senescence of epithelial cells
is arising as a hypothesis for the main initiator event (Chilosi
et al., 2013). Indeed, recent studies found that IPF patients carry
increased number of apoptotic cells in alveolar and bronchial
epithelia (Plataki et al., 2005). The bleomycin mouse model sup-
ports this hypothesis by showing that inhibition of epithelial cell
apoptosis prevents the development of the disease (Kuwano et al.,
1999). This model is widely used in IPF research and shows the
histological features of a ﬁbrotic lung. It does, however, have lim-
itations, as it is steroid responsive and the ﬁbrosis resolves itself
with time (Chandler, 1990), so it does not fully replicate the extent
of the human disease.
What stimuli trigger the apoptotic cascade in epithelial cells
is still under scrutiny. Cell senescence and premature aging due
to genetic factors may be one cause but environmental factors
such as cigarette smoking, viral infections, and gastroesophageal
reﬂux (GER) are a few of the hypothesis that are currently being
investigated.
Genetic mutations of telomerase, an enzyme that adds telom-
ere repeats to the end of linear chromosomes, occur in 10% of
familial IPF (Chilosi et al., 2012). Telomerase is known to main-
tain the precursor function in ATII cells and dysregulation of
this enzyme greatly affects their regenerative capacity. Telomere
shortening is dangerous for the cell as it causes DNA damage
and induces cell death. Another disease-linked mutation that
may lead to alveolar epithelial cell apoptosis occurs in the sur-
factant protein C gene which has also been found in familial
IPF (Thomas et al., 2002). This mutation results in abnormal
surfactant protein folding and accumulation of misfolded pro-
tein in the cell cytoplasm which activates the unfolded protein
response (UPR) in an attempt to rescue the cell from cell death
by halting the protein production. When this mechanism is not
resolved, the cell enters a state of stress, called endoplasmic
reticulum (ER) stress which ultimately leads to apoptosis (Noble
et al., 2012). Other surfactant proteins, surfactant protein A and
D have also been shown to be important mediators of respira-
tory infection susceptibility in mice (LeVine and Whitsett, 2001),
which highlights the role of these proteins in the maintenance of
the epithelial barrier. Environmental factors, like the mentioned
viral infections but also cigarette smoking can induce UPR and
ER stress, and in this way also contribute to accelerated telom-
ere shortening and cellular senescence in the alveolar epithelia
(Tsuji et al., 2004). Polymorphisms in the promoter region of the
MUC5B gene have also been linked to IPF, this time not in ATII
cells, but in bronchial epithelial cells (Seibold et al., 2011), sug-
gesting that broader epithelial cell defects can affect the onset
of disease. More recently, one study has found that MUC5B
promoter polymorphisms were associated with interstitial lung
disease in the general population, independently of cigarette
smoking (Hunninghake et al., 2013). Despite this, in IPF patients,
MUC5B polymorphisms actually associated with increase survival
in another study (Peljto et al., 2013). These potentially contra-
dicting reports underline the complexity of this disease, and
prompt further, more functional studies to better understand
the role of these genetic factors in inducing or driving disease
pathology. A very recent study using genome-wide association
(GWAS) has also identiﬁed 7 new susceptibility loci for pulmonary
ﬁbrosis associated with epithelial cell function, including DSP
which encodes for desmoplakin, a component of the epithelial
cell desmosome, and DDP9, also associated with epithelial cell
adhesion and maintenance of its cytoskeleton (Fingerlin et al.,
2013).
These studies are very important to identify genetic defects that
underline the disease and not only help to increase our knowl-
edge of the mechanisms that drive it but also to aid in ﬁnding
potential therapeutic targets. This understanding may also lead
to better methods of diagnostic, and increase the chances of an
early diagnose that can better help patients. In fact, one study
has looked at peripheral blood proteins and their association with
disease and mortality and identiﬁed that high concentrations of
matrix metalloproteinase 7 (MMP-7), interleukin (IL)-8, intercel-
lular adhesion molecule 1 (ICAM-1), and vascular cell adhesion
molecule 1 (VCAM-1) were associated with poor overall survival.
Altogether, these proteins were shown to be involved in alveolar
epithelial cell damage, oxidative stress, macrophage activation and
neutrophil recruitment, all of which have been described in IPF
(Richards et al., 2012). Lastly, a study of the transcriptional pro-
ﬁles of lung tissue from IPF patients has recently deﬁned new genes
associated with expression of cilium in epithelial cells which deﬁne
particular subtypes of the disease, in this way helping in future
patient stratiﬁcation for therapies. In this study, patients with
high cilium gene expression showed increased microscopic hon-
eycombing, increased tissue expression of MUC5B and MMP-7,
but with no effect on the number of ﬁbroblastic foci, compared
with other patients (Yang et al., 2013).
Genetic factors alone are not however the sole cause of IPF and
it is well known that oxidative stress induced by chronic exposure
to toxic substances, mainly cigarette smoke is a high risk factor
for these patients. Cigarette smoke can induce oxidative stress and
ultimately lead to cell death by causing an excessive production of
reactive oxygen species (ROS), such as hydrogen peroxide, super-
oxide anions, and hydroxyl radicals that cells cannot scavenge
and process (Psathakis et al., 2006). In IPF, the oxidative stress
is continuously present as myoﬁbroblasts that are constitutively
activated by transforming growth factor beta (TGF-β) also pro-
duce high amounts of hydrogen peroxide. This has been elegantly
demonstrated in an in vitro co-culture system whereby TGF-β-
stimulated ﬁbroblasts induced epithelial cell apoptosis through
their production of hydrogen peroxide (Waghray et al., 2005).
Exposure to cigarette smoke cannot, per se, induce IPF disease,
and other chronic lung diseases such as COPD occur due to
several years of cigarette smoke exposure. There are, however,
differences between these two, not only different genetic suscep-
tibilities but also the fact that the epithelial cell seem to be the
main causative cell target in IPF, through senescence or apoptosis
whereas in COPD, senescent markers have been more associ-
ated with mesenchymal cells like ﬁbroblasts and endothelial cells
(Chilosi et al., 2012, 2013).
Other potential initiators of lung ﬁbrosis have been linked
to viral infections, as these represent injury to the epithelium
and lung and also activate the immune system (Figure 2). Some
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FIGURE 2 | Airway remodeling can be initiated by either aberrant
epithelial cell (genetic mutations) or exposure to external irritants.
Genetic mutations in the telomerase enzyme and surfactant protein C
(SP-C) are associated with a senescence phenotype in type II alveolar
cells (ATII), Both these and reactive oxygen species (ROS) formed as a
response to injury (cigarette smoke, asbestos, bleomycin, etc.) can
activate the UPR response and induce ER stress and ultimately apoptosis
in the epithelial cells. These events lead to a senescence- associated
secretory phenotype, where injured epithelial cells release cytokines,
chemokines, and danger-associated molecular patterns (DAMPs) which in
turn recruit leukocytes to the site of injury and also activate the
coagulation cascade, in an attempt to repair the damage. In IPF, these
pathways become dysregulated and inﬂammatory cell types contribute to
the unresolved damage/repair by secretion of TGF -β, IL -13, and ROS,
which provide repeated injury to epithelial cells and induce their
hyper-proliferation. TGF -β is also produced by activated platelets and
contributes to the ﬁbrotic state by inducing EMT, ﬁbroblast proliferation
and collagen synthesis, and ECM deposition.
studies have found both Epstein–Barr virus (EBV) and herpes sim-
plex virus (HSV) in alveolar epithelium of IPF patients, and that
their presence was associated with poor prognosis (Tsukamoto
et al., 2000; Margaritopoulos et al., 2013). Some recent theories
arose that point to gastric contents as another potential cause of
injury to the lungs in IPF, and GER has been associated with acute
exacerbations in these patients (Lee et al., 2012). To support this
observation an in vitro study has shown that a component of bile
could induce TGF-β production by lung epithelial cells and also
ﬁbroblast proliferation, two keymechanistic features of IPF (Perng
et al., 2007).
Once the epithelium is injured, the epithelial/ﬁbroblastic path-
ways of wound healing become activated. The IPF lung shows
a typical loss of integrity of the alveolar epithelium, with dis-
ruption of basement membrane integrity and collapse of the
alveolar structure. The number of ATI cells is reduced whereas
hyperplasia of ATII cells develops. These represent the progeni-
tor cells that are able to differentiate to ATI cells and therefore
re-epithelialize the site where the barrier was broken. However,
the latter is seriously impaired in the IPF lung (Chapman, 2011).
Other mechanisms of lung repair other than epithelial cell prolif-
eration involve amigration of bonemarrow-derivedmesenchymal
stem cells (BM-MSC) into the lung through chemokine gradients
and their differentiation into epithelial cells. However, there are
conﬂicting results on whether this process actually takes place
in IPF (Rojas et al., 2005; Xu et al., 2009). Epithelial damage
also activates ﬁbroblasts to differentiate into myoﬁbroblasts that
then form the characteristic ﬁbroblastic foci. The source of these
myoﬁbroblasts is still under debate but there are currently three
hypotheses of how these cells are generated in the lung. The ﬁrst
one is the migration of local ﬁbroblasts to the site of injury by
expressionof platelet-derived growth factor (PDGF) fromplatelets
and TGF-β and tumor necrosis factor alpha (TNF-α) from the
epithelium and their subsequent differentiation into myoﬁbrob-
lasts (Selman and Pardo, 2006). This hypothesis seems quite
appealing due to the proximity of the cells to each other, and
resting resident ﬁbroblast can be immediately exposed to the
cytokine and chemokine milieu secreted in response to damage
and become activated. However, this may account for the initial
burst of the ﬁbrotic response but may not be sufﬁcient in the
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full blown disease, where myoﬁbroblast take over large sections of
the lungs. The second theory proposes that myoﬁbroblasts may
be derived from circulating CXCR4-positive ﬁbrocytes (or cir-
culating mesenchymal cells), and that these are attracted to the
lung by the high expression of chemokine CXCL12 from epithe-
lial cells (Andersson-Sjoland et al., 2008; Antoniou et al., 2010). In
favor of this hypothesis, a higher number of circulating ﬁbro-
cytes have been found in the blood of IPF patients compared
with healthy controls (Andersson-Sjoland et al., 2008). The third
hypothesis has been given a lot of attention recently and is thought
to occur through a loss of the characteristic epithelial cell phe-
notype, such as E-cadherin expression and the de-differentiation
of the epithelial cell into a myoﬁbroblast by gaining of mes-
enchymal markers like α-smooth muscle actin and ﬁbronectin,
in a process called epithelial-to-mesenchymal transition (EMT;
Willis et al., 2006). TGF-β, the main cytokine regulating ﬁbro-
sis, is thought to drive EMT directly and perpetuate this event in
the lung (Guarino et al., 2009). A key pathway that has been found
dysregulated inﬁbrosis involved inEMT is theWnt-signalingpath-
way. Hyperplastic ATII cells overexpressing the WNT-1 inducible
signaling protein or WISP-1 up-regulate the secretion of pro-
ﬁbrotic markers like MMP-7 and plasminogen-activator inhibitor
1 (PAI-1) which could induce EMT in the neighboring epithelium
(Margaritopoulos et al., 2013).The Wnt pathway has been shown
to be activated by cell senescence, which triggers a “senescence-
associated secretory phenotype” whereby injury-induced apop-
tosis in epithelial cells initiates the release of damage factors or
alarmins that target the neighburing type II alveolar epithelial cells
to induce their proliferation in an attempt to restore homeostasis
(Chilosi et al., 2012).
In addition to above mentioned genetic and environmental
factors that can induce epithelial cell damage in ﬁbrosis and the
mechanisms that it activates (apoptosis, cell proliferation, release
of pro-inﬂammatory, and pro-ﬁbrotic cytokines) which perpetu-
ate the damage/repair response, the mechanical stress to the lung
is another cofactor in inducing alveolar damage. The mechan-
ical stretch focused on limited parts of lung parenchyma has
detrimental effects in alveolar epithelial permeability and tissue
regeneration following injury and has also been showed to increase
the production of ROS (Chilosi et al., 2013; Davidovich et al.,
2013). In fact, inducing mechanical stretch and compression in in
vitro cultures of epithelial cells inhibitedwound closure by inhibit-
ing both cell spreading and cell migration and this was dependent
on the duration of the stretch cycles (Savla and Waters, 1998).
Moreover, αvβ6-mediated activation of TGF-β has been shown to
require cellular tension and thus increased stiffness of the lung
tissue may form a positive feedback loop promoting progression
of the ﬁbrosis (Giacomini et al., 2012).
THE INJURED EPITHELIUM AND THE IMMUNOLOGICAL
RESPONSE
Despite immune suppressors, such as steroids having had little
to no effect in the clinic for the treatment of IPF, injury to the
epithelium typically elicits an immune response in the lung. The
coagulation cascade is the ﬁrstmechanism activated in thewound-
healing process, and activated platelets release pro-ﬁbrotic factors
like PDGF and TGF-β1 (Chambers, 2008). Damaged epithelial
cells release a variety of the chemokines that recruit inﬂamma-
tory monocytes and neutrophils to the site of injury. In a single
injury, such as infection or allergen exposure, monocytes differ-
entiate into phagocytic macrophages that phagocytose the ﬁbrin
clot and neutrophils remove debris and kill invading bacteria. In
the case of repeated injury such as the one occurring in COPD
and IPF, neutrophils and macrophages are not eliminated quickly
enough and their presence can further exacerbate the ﬁbrotic cas-
cade by continuous production of ROS (Wynn and Ramalingam,
2012). The recruitment of neutrophils to the bronchoalveolar
space is considered a predictor of early mortality in IPF patients
(Kinder et al., 2008), and both macrophages and neutrophils have
been identiﬁed as pro-ﬁbrotic cell types in mouse models of pul-
monary ﬁbrosis (Pardo et al., 2000; Dufﬁeld et al., 2005). Other
innate myeloid cell types that have also been suggested as hav-
ing a pro-ﬁbrotic role in the lung include eosinophils and mast
cells (Wynn and Ramalingam, 2012) and, more recently a newly
identiﬁed cell type, innate lymphoid cells 2 (ILC2) has also been
implicated as a mediator of hepatic ﬁbrosis (McHedlidze et al.,
2013). Within the adaptive immune system, there is some evi-
dence that CD4+ Th1, Th2, and Th17 subtypes may play role
in pulmonary ﬁbrosis and their plethora of cytokines such as
interferon gamma (IFN-γ) for Th1 and IL-4 and IL-13 for Th2
cells have been linked to disease development in the lung (Wynn,
2011). Interestingly, IPF ﬁbroblasts are hyperresponsive to IL-13,
and increased expression of IL-13 and its receptor IL-13R-α1 cor-
relate with disease severity (Murray et al., 2008). As well as its
direct effects on ﬁbroblast proliferation and epithelial cell apop-
tosis (Borowski et al., 2008), IL-13 can also target TGF-β directly
in vivo which further augments the ﬁbrotic response (Lee et al.,
2001). The strategy of targeting IL-13 in IPF is currently undergo-
ing clinical trials. Regulatory T cells have also been associated
with IPF, however, there is still some controversy to whether
their role in IPF is pro- or anti-ﬁbrotic (Kotsianidis et al., 2009;
Liu et al., 2010).
Toll-like receptor (TLR) activation in epithelial cells by could
be the trigger responsible for the epithelial-induced immune cell
recruitment to the lungs and TLR signaling pathways have also
been linked with tissue repair, as they can promote tissue remod-
eling (Jiang et al., 2005). In line with the hypothesis of viral
infections as one of the insults that could initiate IPF, TLR9 (that
recognizes nuclei acid strands) has been found overexpressed in
ﬁbroblast of IPF patients (Margaritopoulos et al., 2010). In a more
recent study, TLR2 was also found up-regulated in the lungs of
IPF patients compared with healthy controls (Samara et al., 2012).
This receptor has also been found to be critical for the release
of pro-inﬂammatory cytokines and promotion of collagen and
ﬁbronectin deposition following bleomycin exposure (Razonable
et al., 2006; Yang et al., 2009). In addition, in a radiation-induced
lung ﬁbrosis model, both TLR2 and TLR4 were found to have a
protective effect by preventing epithelial cell injury and suppress-
ing ﬁbrogenesis (Paun et al., 2010). Activation of TLR2 and TLR3
can also induce up-regulation of mucin expression (Li et al., 1997;
Chen et al., 2004), and therefore a dysregulation of TLR signaling
can impact not only the type of immune response initiated but
also the balance of mucous production and clearance. This can
have a major impact during viral exacerbations in IPF patients,
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which are one of the major causes of mortality in these patients.
A recent study places TLR3 as an important factor in IPF. It was
found that in IPF-derived ﬁbroblasts carrying the TLR3 L412F
polymorphism, TLR3 activation resulted in abnormal cytokine
production. Moreover, TLR3-deﬁcient mice showed increased
collagen production in the lungs following bleomycin-induced
ﬁbrosis and patients carrying this polymorphism had signiﬁcantly
greater risk of mortality and accelerated decline in forced vital
capacity (O’Dwyer et al., 2013).
Though well-known sentinels for the recognition of pathogen
speciﬁc patterns, TLRs have also been shown to identify some
endogenous ligands, including fragmented forms of hyaluronic
acid (a major component of ECM in most organs) which could
signal through TLR2 and TLR4 receptors in immune cells (McKee
et al., 1996; Scheibner et al., 2006). Other endogenous TLR ligands
reported include HMGB1, signaling through TLR2 and TLR4.
HMGB1 is a nuclear protein that can either be released by either
activated immune cells following inﬂammation or by necrotic cells
(Scafﬁdi et al., 2002). More recently, ﬁbrinogen cleavage prod-
ucts have also been found to act as TLR4 ligands in both alveolar
macrophages and epithelial cells, and that this interaction up-
regulated the gene expression of IL-13Rα1 and MUC5AC in both
these cell types (Millien et al., 2013). These endogenous patterns
are usually referred to as danger-associated molecular patterns
(DAMPs) and it can be easily hypothesized that they may be of
importance in chronic lung diseases where the epithelial barrier
is severely damaged, although further studies will be needed to
identify the extent to which they may either cause it or contribute
to their perpetuation.
An autoimmune response has been also suggested as part
of the IPF pathology, where B cell aggregates were found in
patient’s lungs and circulating activated CD4 T cells in their
serum (Marchal-Somme et al., 2006). Indeed some studies have
found circulating auto-antibodies against epithelial antigens in
the serum of IPF patients, including antibodies against cytok-
eratins and, more recently an anti-periplakin antibody (Fahim
et al., 2012). The latter was shown to delay wound repair in vitro,
by decreasing epithelial cell migration (Taille et al., 2011). There-
fore, there is some evidence of a chronic inﬂammatory setting
in IPF, however, further investigation is warranted to understand
whether this is caused by the aberrant wound-healing and perma-
nent secretion of pro-inﬂammatory modulators by epithelial cells
and ﬁbroblasts, or whether the initial lung injury provokes a dereg-
ulated immune response and the immune cell-derived cytokines
perpetuate the aberrant apoptosis/cell proliferation in epithe-
lial cells and the continuous differentiation and proliferation of
myoﬁbroblasts.
TGF-β AS A MOLECULAR MEDIATOR OF IPF
TGF-β is a member of the TGF-β superfamily and exists in
three different forms in mammals which are expressed through-
out the body (TGF-β1, TGF-β2, and TGF-β3) (Moustakas and
Heldin, 2009). TGF-β signaling is important for morphogene-
sis during embryonic development and in adulthood, for tissue
homeostasis, however, in injured tissue, TGF-β acts as a major
pro-ﬁbrotic cytokine, inducing ﬁbroblast recruitment, prolifera-
tion and differentiation of myoﬁbroblasts, and deposition of ECM
(Sheppard, 2006). The role of TGF-β is therefore well described
in IPF; it is overexpressed in both patients (Coker et al., 2001)
and animal models of lung ﬁbrosis and blocking TGF-β signal-
ing improves pulmonary ﬁbrosis in mouse models (Bonniaud
et al., 2005). TGF-β1 is produced as a complex of active TGF-
β1 non-covalently associated with the latency-associated peptide
(LAP) and these complexes are sequestered in the ECM. In order
to exert its biological function TGF-β must be released from
these complexes. This process can be caused by physical mech-
anisms such acidiﬁcation, and oxidation, which could be initiated
by injury, for example, from asbestos exposure (Sullivan et al.,
2008). TGF-β can also be cleaved by proteases such as MMP-2
and MMP-9 (Jenkins, 2008). More relevant to the epithelium is
that epithelial cell integrins, more speciﬁcally αvβ6 can induce
conformational changes in the latent TGF-β complexes, and this
process has been found to be a key event in pulmonary ﬁbrosis
(Tatler and Jenkins, 2012). The role of integrins will be further
explored in the next section of this review. Once released from
the latent complexes, TGF-β can interact with its receptors on
the surface of ﬁbroblasts, and in the canonical signaling path-
way it phosphorylates Smad proteins (Smad2 and Smad3) which
then heterodimerise with Smad4 to form Smad2/4 and Smad3/4
complexes that translocate to the nucleus and bind to the pro-
moter regions of pro-ﬁbrotic genes like collagen, ﬁbronectin,
and α-smooth muscle actin (Santibanez et al., 2011). In the
non-canonical activation pathways, the c-Abelson tyrosine kinase
(c-Abl) andmitogen-activated protein kinase (MAPKs) have been
shown to be directly activated by TGF-β (Daniels et al., 2004; Hu
et al., 2006). In contrast to the effects of protecting ﬁbroblasts
from apoptosis and inducing their differentiation, TGF-β pro-
motes apoptosis in lung epithelial cells, and this has been shown
both in vitro (Solovyan andKeski-Oja,2006) and in amousemodel
where protection from bleomycin-induced ﬁbrosis was achieved
in animals harboring a epithelial-speciﬁc deletion of the TGF-β
type II receptor (Li et al., 2011). This way TGF-β is a bidirec-
tional modulator, affecting both epithelial cells and ﬁbroblasts
in IPF.
EPITHELIAL CELL INTEGRINS AND CHEMOKINES
Integrins are heterodimeric transmembrane receptors made up of
one α and one β subunit which bind to ECM proteins. So far 26
combinations have been identiﬁed. They function by transducing
information between the ECM and the inside of the cell and have
important roles in adhesion, migration, survival, differentiation,
invasion, and maintenance of cell shape. In vitro, αVβ3, αVβ5,
αVβ8, and αVβ6 can all activate TGF-β1 and TGF-β2 through
binding of the arginine–glycine–aspartate (RGD) motif which is
present in the LAP of the latent complex of TGF-β, although αVβ6
and αVβ8 are higher afﬁnity binders. In vivo, however, the role
for αVβ6 and αVβ8 in TGF-β activation is still under investiga-
tion, although expression of αVβ3 and αVβ5 is up-regulated in
systemic sclerosis and αVβ5 is detected in the ﬁbroblast foci of
patients with IPF (Asano et al., 2005). Upon binding of LAP to
αVβ6 or αVβ8, cleavage or conformational change occurs, allow-
ing the active TGF-β to interact with its receptor (Figure 3). The
mechanisms bywhich αVβ6 and αVβ8 activate TGF-β are different
however. For αVβ6, mechanical stretching of the cells results in a
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FIGURE 3 | Integrin activation ofTGF-β can occur via αVβ6 (A) and αVβ8
(B). Integrin αVβ6 is restricted to the epithelium and can activate TGF -β
following mechanical tension of the cells alongside binding of the large latent
complex (LLC) to αVβ6 and extracellular matrix (ECM) proteins. This tension
exposes the active TGF -β through opening of the latency-associated peptide
(LAP) allowing it to bind to its receptor on neighboring epithelial cells only as
TGF -β is not released from the cell surface. Integrin αVβ8 requires
metalloproteolytic cleavage by MMP-14 which results in TGF -β being
liberated from its latent complex and therefore acting on cells by paracrine
diffusion. Although integrin αVβ8 is more widely expressed on several
subsets of cells, metalloprotease expression is required for it to activate TGF
-β (ﬁgure adapted from Nishimura, 2009).
conformational change of the latent complex revealing the active
TGF-β peptide and allowing it to bind to its receptor on cells in
direct contact with each other. On the other hand, αVβ8 requires
proteolytic cleavage with the help of MMP-14 releasing the active
TGF-β peptide from the latent complex and allowing it to inter-
act with its receptor in a paracrine fashion (Annes et al., 2003).
The integrin αVβ8 has been shown to be expressed on several cell
types such as epithelial, ﬁbroblast, neural, and immune whereas
αVβ6 is predominantly expressed on epithelial cells (Munger et al.,
1999). Under normal conditions αVβ6 is expressed at low lev-
els and further induced by inﬂammatory mediators unlike αVβ8
which it is expressed at high levels in the normal airway epithe-
lium. This suggests αVβ6 may be more predominant at TGF-β
activation during epithelial injury. During epithelial injury, dam-
age to the basement membrane further allows αVβ6-expressing
epithelial cells to interact with other cell types such as mes-
enchymal cells allowing TGF-β to exert ﬁbrotic effects upon other
cells.
In mice that do not express the β6 integrin subunit there is a
decrease in active TGF-β in the lung (Jenkins et al., 2006) and these
mice can develop MMP-12-dependent emphysema suggesting
epithelial speciﬁc activation of TGF-β in vivo is important. In
addition blockade of αVβ6 either in knockout mice or through
antibody neutralization protects mice from bleomycin induced
ﬁbrosis emphasizing its importance in ﬁbrogenesis. Furthermore
patients diagnosed with lung ﬁbrosis also show enhanced levels
of αVβ6 and currently there is an anti- αVβ6 (STX-100) from
Stromedix in clinical development for organ ﬁbrosis.
Angiogenesis occurs as part of the wound healing pro-
cess and it has been described around the ﬁbroblastic foci
in both IPF patients and in the bleomycin model (Cui et al.,
2001; Sterclova et al., 2009). CXC chemokines are important fac-
tors in the angiogenic–angiostatic balance as well as being
powerful chemoattractants for inﬂammatory cells (Gerard and
Rollins, 2001). These can be further divided into two subgroups:
ELR + CXC (pro-angiogenic) binding to CXCR2 or ELR–CXC
(anti-angiogenic) biding to CXCR3, depending on the presence
or absence of a glutamate–leucine–arginine (ELR) motif, respec-
tively (Strieter et al., 1995). To date, several CXC chemokines
have been implicated in IPF (Figure 2). IL-8 (or CXCL8), a
potent neutrophil chemoattractant produced by epithelial cells,
endothelial cells, and macrophages has been shown elevated in
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BAL ﬂuid, lung tissue, and serum of IPF patients (Prasse and
Muller-Quernheim, 2009). Recently, another epithelial-derived
chemokine, CXCL6 (or GPC-2) was shown to be elevated in
BAL ﬂuid of both IPF patients and in the bleomycin model and
that therapeutic blockade of this chemokine in this model signif-
icantly decreased both inﬂammation and some ﬁbrosis markers
(Besnard et al., 2013). In contrast, angiostatic CXC-chemokines
such as CXCL10/IP-10 and CXCL11/I-TAC were found to de
decreased in IPF patients (Sterclova et al., 2009). Apart from these,
CC chemokines such as CCL2/MCP-1 has also been shown as
important effectors in IPFpathogenesis by recruitingmacrophages
to the lung (Agostini and Gurrieri, 2006). Moreover CCL2 has
been recently found to be expressed in airway epithelial cells
(Mercer et al., 2009).
Two studies have found that IFN-γ-1b therapy could have
beneﬁcial effects in IPF by regulating the angiogenic balance
in IPF. One study found that subcutaneous IFN-γ-1b delivery
three times weekly for 6 months, increased CXCL11/I-TAC in
both BAL ﬂuid and plasma and that CXCL5 and type I collagen
were signiﬁcantly reduced (Strieter et al., 2004). The second study
showed that several pro-angiogenic chemokines such as IL-8 and
CXCL5 were up-regulated following IFN-γ-1b treatment but no
changes were seen in the levels of IP-10 or I-TAC (Antoniou et al.,
2008). Moreover, they did not see any correlation with improve-
ment in lung physiology or disease outcome. Therefore further
research is needed to fully understand the potential beneﬁts of this
drug.
SUMMARY AND FUTURE DIRECTIONS
Idiopathic pulmonary ﬁbrosis is a complex disease that is refrac-
tory to treatment and carries a high mortality rate. The pharma-
ceutical and biotechnology industry have made many attempts
to ﬁnd effective treatments for IPF, but the disease has so far
deﬁed all attempts at therapeutic intervention. Clinical trial fail-
ures may arise for many reasons, including disease heterogeneity,
lack of readily measurable clinical end points other than over-
all survival, and, perhaps most of all, a lack of understanding
of the underlying molecular mechanisms of the progression of
IPF. The anti-ﬁbrotic drug Esbriet (pirfenidone) is the only drug
marketed for IPF, however, it is not yet approved in the US.
Other promising candidates in clinical development include the
tyrosine kinase inhibitor nintedanib in Phase III (Boehringer
Ingelheim), the monoclonal antibodies tralokinumab (MedIm-
mune: AstraZeneca) and lebrikizumab (GenenTech) targeting
anti-IL-13, the monoclonal antibody STX-100 against integrin
αVβ6 (Biogen Idec), the lysophosphatidic acid 1 inhibitor (Bristol-
Myers Squibb) and the monoclonal antibody simtuzumab against
lysyl oxidase-like 2 (Gilead) in Phase II.
Other trials targeting the immune system, using steroids as
immune suppressants have had less success, and in fact have
been associated with deleterious effects in IPF (The Idiopathic
Pulmonary Fibrosis Clinical Research Network, 2012). How-
ever, despite current advances in technology and other current
therapies in the clinic, lung transplantation is the only current
available treatment for IPF that has been shown to improve sur-
vival (Adamali and Maher, 2012), but it carries the downside risks
of donor availability, infection, and organ rejection.
A deeper understanding of the mechanisms that initiate the
ﬁbrotic pathway is urgently needed in order to develop more
appropriate and more speciﬁc therapies. Accumulating evidence
suggests that alveolar epithelial cell apoptosis may be the initial
trigger of the disease and both genetic background and envi-
ronmental exposure contribute to this outcome and initiate the
“senescence-associated secretory pathway” that ultimately leads to
full blown disease. It is imperative to ﬁnd the common ancestor
and disease initiator, so that patients can be identiﬁed earlier in
the clinic and perhaps have more adequate treatment. Since this is
a complex disease involving multiple pathways, it is possible that
the future best therapies will involve combination drugs that target
more than one pathway.
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